Japan Animal Referral Medical Center (6039) Fundamentals 2026 — P/E 15.4x, Revenue Analysis | SniperIQ
Japan Animal Referral Medical Center (6039) is a JP-listed Consumer Cyclical company in Personal Products & Services with a market capitalization of ¥12.8B, trading at ¥993.00 on the JPX. This SniperIQ fundamentals page covers Japan Animal Referral Medical Center's valuation (P/E 15.4x, P/B 2.6x), profitability (net margin 13.5%), revenue (¥6.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Japan Animal Referral Medical Center's market cap?
Japan Animal Referral Medical Center (6039) has a market capitalization of approximately ¥12.8B, trading at ¥993.00 on the JPX. Market cap moves with the live share price.
What is Japan Animal Referral Medical Center's P/E ratio?
Japan Animal Referral Medical Center's trailing twelve-month P/E ratio is 15.4x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Consumer Cyclical sector peers rather than read in isolation.
How profitable is Japan Animal Referral Medical Center?
Japan Animal Referral Medical Center runs a net profit margin of 13.5%, a gross margin of 40.5%, and an operating margin of 18.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Japan Animal Referral Medical Center generate?
Japan Animal Referral Medical Center reported revenue of ¥6.2B for fiscal year 2025, with net income of ¥833M and earnings per share (EPS) of 64.49. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Japan Animal Referral Medical Center pay a dividend?
Japan Animal Referral Medical Center offers a trailing dividend yield of about 1.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Japan Animal Referral Medical Center financially healthy?
Japan Animal Referral Medical Center carries a debt-to-equity ratio of 1.06x and a current ratio of 0.56x, with a market beta of 0.65. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Japan Animal Referral Medical Center a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Japan Animal Referral Medical Center (6039) the key facts are: market cap ¥12.8B, P/E 15.4x, revenue ¥6.2B, 52-week range 524.2-1605. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Cyclical peers and form your own view.
Track Japan Animal Referral Medical Center's full fundamentals live
Get Japan Animal Referral Medical Center's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.